Optometrists in Red Hook, NY Accepting Medicare
5 Optometrists found. Showing 1 - 5
 Dr. James George Cayea, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 7381 S Broadway, Red Hook, NY 12571 Phone: 845-758-8818 Fax: 845-758-9215 |
 Dutchess Optometry, Llp Optometrist - Low Vision Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 7381 S Broadway, Red Hook, NY 12571 Phone: 845-758-8818 Fax: 845-758-9215 |
Dutchess Optometry, Llp Optometrist Medicare: Medicare Enrolled Practice Location: 7381 S Broadway, Red Hook, NY 12571 Phone: 845-758-8818 Fax: 845-758-9215 |
 Dr. Tracy Sherman Sheedy, O.D. Optometrist - Low Vision Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 7381 S Broadway, Red Hook, NY 12571 Phone: 845-758-8818 Fax: 845-758-9215 |
Nikki Takahashi Optometrist Medicare: Medicare Enrolled Practice Location: 7381 S Broadway, Red Hook, NY 12571 Phone: 845-758-8818 Fax: 845-758-9215 |
News Archive
BioSpecifics commences XIAFLEX Phase II trial in human lipoma
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that it has initiated its Phase II trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of human lipoma.
Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16
Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.
Scientists discover genetic cause of extreme thinness
Scientists have discovered a genetic cause of extreme thinness for the first time, in a study published today in the journal Nature.
Collaborations and co-achievements of network of COST Actions on COVID-19
Addressing societal issues by enabling cross-disciplinary partnerships is an inherent part of a COST Actions' nature. But collaborations don't stop at the gate of these specific networks: multiple COST Actions have joined forces since the beginning of the pandemic to help advance research into COVID-19.
AstraZeneca receives 2010 EcoLeadership Award for second consecutive year
AstraZeneca announced today it has received the 2010 EcoLeadership Award by the Alliance for Workplace Excellence for the second consecutive year. The EcoLeadership Award recognizes companies that demonstrate their commitment to environmental sustainability practices such as energy efficiency, waste minimization and water conservation.
› Verified 5 days ago
Speech-Language Pathologists
Chiropractors
Occupational Therapists
Optometrists
Physical Therapists
Podiatrists